Stockscreener 앱 받기
1.33
3.62%
-0.05
시장 영업 전:
1.30
-0.03
-2.26%
전일 마감가:
$1.38
열려 있는:
$1.42
하루 거래량:
164.90K
Relative Volume:
0.49
시가총액:
$6.93M
수익:
-
순이익/손실:
$-18.68M
주가수익비율:
-0.1799
EPS:
-7.3948
순현금흐름:
$-15.70M
1주 성능:
-2.21%
1개월 성능:
-3.62%
6개월 성능:
-82.04%
1년 성능:
-93.01%
1일 변동 폭
$1.31
$1.425
1주일 범위
$1.25
$1.51
52주 변동 폭
$1.03
$22.60
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.33 | 6.93M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Canada
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics CEO Issues Letter to Shareholders - GlobeNewswire
FibroBiologics Grants Stock Options to Key Executives - TipRanks
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics (FBLG) CEO receives 92,410 options vesting over 4 years - Stock Titan
FibroBiologics (FBLG) CSO granted 61,607 stock options at $1.38 - Stock Titan
FibroBiologics (FBLG) CFO awarded 61,607 stock options at $1.38 - Stock Titan
FibroBiologics grants options to general counsel | FBLG Insider Trading - Stock Titan
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com Australia
FibroBiologics reports preclinical burn wound treatment results - Investing.com
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - The Manila Times
In mice, a topical cell treatment eased burn inflammation in 8 days - Stock Titan
Maxim Group Downgrades FibroBiologics(FBLG.US) to Hold Rating - Moomoo
FibroBiologics releases first batch of diabetic ulcer drug By Investing.com - Investing.com Australia
FibroBiologics releases first batch of diabetic ulcer drug - Investing.com
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - The Manila Times
Diabetic foot ulcer trial nears enrollment as drug batch clears tests - Stock Titan
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
Certain Common Stock of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
Certain Stock Options of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens - TipRanks
FibroBiologics Launches New At-The-Market Equity Offering - TipRanks
Regenerative medicine company FibroBiologics (stock code: FBLG) recently filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that it has signed an At Market Issuance (ATM) agreement. - Bitget
[424B5] FibroBiologics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
FibroBiologics (NASDAQ: FBLG) sets up $6,150,000 at-the-market stock program - Stock Titan
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - The Manila Times
FibroBiologics Reports Q1 2026 Financial Results and Corporate Updates on Clinical Advancements - Quiver Quantitative
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FibroBiologics (FBLG) low cash, $5M loss and going concern risk - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Preclinical psoriasis data from FibroBiologics heads to Chicago meeting - Stock Titan
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 - The Manila Times
FibroBiologics (FBLG) price target decreased by 76.25% to 19.38 - MSN
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics (FBLG) price target increased by 1,584.21% to 81.60 - MSN
Return on invested capital % of FibroBiologics, Inc. – LSX:A426UV - TradingView
FibroBiologics (FBLG) asks shareholders to OK March warrant issuances, equity plan - Stock Titan
FibroBiologics regains Nasdaq compliance on listing standards By Investing.com - Investing.com India
FibroBiologics regains Nasdaq compliance on listing standards - Investing.com
FibroBiologics Secures Nasdaq Listing Compliance, Under Monitoring - TipRanks
Fibrobiologics compliant with all Nasdaq listing requirements - marketscreener.com
FibroBiologics confirms Nasdaq compliance; listing matter closed, one-year monitors remain - TradingView
FibroBiologics Compliant with All Nasdaq Listing Requirements - TradingView
FibroBiologics (Nasdaq: FBLG) clears listing issues but faces one-year monitor - Stock Titan
FibroBiologics Lowers Quorum Requirement in Amended Bylaws - TipRanks
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):